This study is being conducted to evaluate whether the investigational drug Dovitinib, can
shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors.
This study will also further evaluate the safety of this drug.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Collaborators:
Beth Fox, MD , Sponsor Investigator Stephen Keefe,MD, Principal Investigator